SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Top Story - Biocon seals Rs 1,550 crore pact with Pfizer

19 Oct 2010 Evaluate

Biocon has entered into a $350-million (Rs 1,550 crore) strategic alliance with drug-major Pfizer on marketing Biocon’s insulin products. The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insulin, glargine, aspart and lispro,. 

Under the terms of the agreement, Pfizer will make upfront payments of $200 million. Biocon is also eligible to receive an additional development and regulatory milestone payment of up to $150 million. In addition to the $350 million, the company will also receive additional payments linked to Pfizer’s sales of its four insulin biosimilar products across global markets. The company will launch recombinant human insulin in emerging markets in the first phase and then introduce it in Europe in 2012 with the timeline for introduction in the US in 2015

The potential market for these four products, according to Kiran Mazumdar Shaw , chairman and MD of Biocon, would roughly be around $20 billion by 2015. Biocon hopes to combine the synergies of Pfizer’s marketing and distribution networks and its own cost-effective developing and manufacturing capabilities to grab a piece of the $14-billion biosimilar market. 

crackcrack

Biocon Share Price

361.40 2.90 (0.81%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×